Kidney cancer is a type of cancer which starts in kidney cells. Two major types of kidney cancer include transitional cell carcinoma (TCC) and renal cell carcinoma (RCC). Different types of kidney cancer get developed in different ways which imply different long-term outcomes. This cancer originates in two principal locations of the kidney – the renal pelvis and the renal tubule.
Request 100 Page Sample Report Now: https://www.factmr.com/connectus/sample?flag=S&rep_id=57
A new report published by Fact.MR estimates the global Kidney Cancer Diagnostics Market to exhibit an impressive expansion at during the forecast period 2017 to 2022. In terms of revenues, the global market for kidney cancer diagnostics will reach nearly US$ 700 Mn by 2022-end.
Targeted Systemic Therapies for Metastatic Kidney Cancer are Providing Significant Benefits to Survival and Progression
Over the past few years, the diagnosis and management of kidney cancer, or, renal cell carcinoma (RCC), have undergone tremendous transformations. A number of discoveries, studies, and trails are being taken in renal mass biopsy, minimally-invasive thermal ablation, and active surveillance, owing to the surge in diagnosis rate of small renal masses, usually in patients with high morbidity risks related to operative treatment. In addition, targeted systemic therapies associated with metastatic kidney cancer have replaced cytokine-based treatment, providing significant benefits to survival and progression. Recent trails and reviews have cemented the partial nephrectomy’s role as the standard diagnosis-based surgical management option for majority of low-stage masses, and roles of adrenalectomy and lymphadenectomy pertaining to nephrectomy. These incidences are estimated to augment growth of the global kidney cancer diagnostics market.
Kidney cancer has been witnessed to occur majorly in older population. Diagnosis of kidney cancer becomes an intricate task, considering the condition of geriatric patients. While staple diagnostic technologies such as MRI and CT scan continue to play a pivotal role in the global market, patients are also expecting the emergence of all-inclusive diagnosis tests. Medical organizations are also funneling high investments in R&D of kidney cancer diagnostics, particularly to improve the precision of early stage diagnosis tests. Through advancements in medical technology, the global market for kidney cancer diagnostics is also expected to witness emergence of new tests that can simultaneously decelerate the pace of tumor maturation between multiple stages of kidney cancer.
Get Access To TOC Covering 200+ Topics: https://www.factmr.com/report/57/melanoma-cancer-diagnostics-market
Hospital-associated Labs will Remain Preferred for Kidney Cancer Diagnostics
On the basis of end-users, hospital-associated labs are estimated to remain preferred for kidney cancer diagnostics, accounting for the largest revenues by 2022-end. Independent diagnostic laboratories will continue to be the second most lucrative end-users in the global kidney cancer diagnostics market. In addition, cancer research institutes are expected to register the highest CAGR in the market through 2022.
Immunochemistry tests will continue to be sought-after for kidney cancer diagnostics, with revenues expected to reach US$ 351.8 Mn by 2022-end. This test type segment is projected to register the highest CAGR in the market through 2022, followed by complete blood count test.
Urine analysis will remain the second largest adopted tests for kidney cancer diagnostics across the globe. However, revenues from blood chemistry tests of kidney cancer diagnostics will continue to be lower as compared to rest of the test segments in the market.
North America to Remain the Largest Market for Kidney Cancer Diagnostics
In terms of revenues, North America is expected to remain the largest market for kidney cancer diagnostics, followed by Europe. However, kidney cancer diagnostics market in Europe will exhibit a comparatively higher CAGR than North America during the forecast period. In addition, Asia Pacific excluding Japan (APEJ) will continue to be the fastest expanding market for kidney cancer diagnostics through 2022.
Myriad Genetics Inc, NeoGenomics Laboratories, NanoString Technologies Inc., Sysmex Corporation, Rosetta Genomics, Illumina, Inc., Quest Diagnostics Incorporated, Roche Holding AG, Thermo Fisher Scientific Inc., and Abbott Laboratories are observed as key players in the global market for kidney cancer diagnostics.
Ask Industry Expert about this Report: https://www.factmr.com/connectus/sample?flag=AE&rep_id=57